Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors. Gastroenterol Res. 2018;11(4):264-273 doi: https://doi.org/10.14740/gr1062w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 4×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundInfluentialImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Interestingly, tumor infiltrating lymphocytes express high level of PD-L1, which is thought to be a result of chronic stimulation because of the neoantigen load [86].”
Background
Cited by
Items 201–300 of 581
The prognostic value of TILs in stage III colon cancer must consider sidedness
Moreno, V. R., Salazar, R., & Gruber, S. B. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.155 · Cited by 11
Prognostic Impact of Type 2 Diabetes in Metastatic Colorectal Cancer
Baleiras, M. M., Domingues, T. D., Severino, E., Vasques, C., Neves, M. T., Ferreira, A., de Matos, L. V., Ferreira, F., Miranda, H., & Martins, A. (2023) · Cureus · doi:10.7759/cureus.33916 · Cited by 13
“RSCC is generally associated with poor prognosis and does not respond well to conventional chemotherapy [19].”
BackgroundClinical and Histopathological Characteristics of Colorectal Cancer in Iraq between 2015-2021.
Soliman, N. F., & Mohamad, B. J. (2022) · PubMed Central · doi:10.22092/ari.2022.358613.2263 · Cited by 16
Diverging likelihood of colon and rectal cancer in Yogyakarta, Indonesia: A cross sectional study
Puspitaningtyas, H., Hutajulu, S. H., Fachiroh, J., Anggorowati, N., Sanjaya, G. Y., Lazuardi, L., & Sripan, P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301191 · Cited by 10
“In addition, colon cancer has a flat morphology, making it more frequently diagnosed at a later stage and with poor differentiation [11].”
InfluentialKuliavas, J., Marcinkevičiūtė, K., Baušys, A., Bičkaitė, K., Baušys, R., Abeciūnas, V., Degutytė, A. E., Kryžauskas, M., Stratilatovas, E., Dulskas, A., et al. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04623-w · Cited by 8
“…in the DNA mismatch repair pathway are often found in RCC tumors, which are more sensitive to immuno-therapy and less sensitive to chemotherapy, whereas LCC tumors are usually characterized by molecular mutations in the chromosomal instability pathway, which is better affected by chemotherapy [25].”
BackgroundIkuta, S., Saito, Y., Takata, S., Nakatani, Y., Nagatomo, I., Shiba, S., Takeda, Y., Totoki, Y., Mizutani, S., Sunakawa, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02159-9 · Cited by 9
“Mutations in the DNA mismatch repair pathway play a significant role in right-sided colon cancer [11].”
McCabe, M., Penny, C. B., Magangane, P. S., Mirza, S., & Perner, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-10185-3 · Cited by 12
Langheinrich, M. C., Siebenhüner, A. R., Baecker, J., Miragall, M. F., Wiesmueller, F., Schellerer, V. S., Merkel, S., Brunner, M., Krautz, C., Weber, K., et al. (2022) · Diagnostics · doi:10.3390/diagnostics13010116 · Cited by 8
“In addition to the differentiation between the colon and rectum, tumor location (right-sided versus left-sided colon cancer) is widely accepted as a crucial factor determining disease progression and prognosis and influencing disease management [36,37].”
BackgroundPrognostic Significance of MRE11 Overexpression in Colorectal Cancer Patients
Ho, V., Chung, L., Wilkinson, K. J., Lea, V., Lim, S. H.-S., Abubakar, A., Ng, W. L., Lee, M., Roberts, T. L., Chua, W. M., et al. (2023) · Cancers · doi:10.3390/cancers15092438 · Cited by 10
Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal Cancer
Heuvelings, D. J. I., Wintjens, A. G. W. E., Moonen, L., Engelen, S. M. E., Iersel, L. V., Dulk, M. D., Beckervordersandforth, J., Thijssen, S., Leunissen, D. J. G., Stassen, L. P. S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612830 · Cited by 10
Xiong, J., Wu, Y., Chen, D., Zhang, Z., Liu, Y., Luo, J., & Xu, H. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03220-z · Cited by 9
“Approximately 90% of CRC progresses from colorectal adenomas [4].”
BackgroundGenomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer
Zhou, Y., Chen, X., Chen, J., Kendrick, C. D., Ramanathan, R. K., Graham, R. P., Kossick, K. F., Boardman, L. A., & Barrett, M. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-59398-5 · Cited by 8
Kim, J. H., Wang, J., Pence, C., Magahis, P. T., Dawod, E., Schnoll‐Sussman, F. H., Sharaiha, R. Z., & Wan, D. W. (2025) · Clinical Endoscopy · doi:10.5946/ce.2024.271 · Cited by 10
“23 In addition, the near-doubling in both the 1 to 5 mm and right-sided SSLDR associated with the combined use of GI Genius and EndoCuff was also notable, as it has been estimated that up to 20% of colon cancers develop from SSL, 24 and the overall miss rate of SSL on colonoscopy is as high as 27%.”
Morcet-Delattre, R., Duvergé, L., Bourbonne, V., Scodan, R. L., Lapierre, A., Pointreau, Y., Argo-Leignel, D., Kinj, R., Bellec, J., Vaugier, L., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110992 · Cited by 8
Uhlyarik, A., Piurkó, V., Vízkeleti, L., Pápai, Z., Rásó, E., Lahm, E., Kiss, É., Sikter, M., Vachaja, J., Kenessey, I., et al. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-018-00572-2 · Cited by 9
Herold, Z., Dank, M., Herold, M., Nagy, P., Rosta, K., & Somogyi, A. (2020) · Cancers · doi:10.3390/cancers13010067 · Cited by 8
Al-Shandudi, M., Al-Moundhri, M. S., Chan, M. F., Al-Hajri, T., Al-Balushi, M., & Al-Azri, M. H. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.9.3019 · Cited by 8
“Left-sided CRC patients appear to benefit more from chemotherapy and have a better prognosis and survival rate, whereas right-sided CRC patients are diagnosed at more advanced stages and do not respond well to chemotherapy, with a greater chance of recurrence (Baran et al., 2018).”
BackgroundLi, P., Meng, Q., Xue, Y., Teng, Z., Chen, H., Zhang, J., Xu, Y., Wang, S., Yu, R., Ou, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000146 · Cited by 9
Arora, B., Kulkarni, A., Markus, M. A., Ströbel, P., Bohnenberger, H., Alves, F., & Ramos‐Gomes, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-58231-3 · Cited by 9
“There is an ongoing debate on the question which side of colorectal cancer has a poorer prognosis 40 .”
BackgroundNomograms for Prediction of Molecular Phenotypes in Colorectal Cancer
Yu, Z., Yu, H., Zou, Q., Huang, Z., Wang, X., Tang, G., Bai, L., Zhou, C., Zhuang, Z., Xie, Y., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s234495 · Cited by 8
“The tumors located in ascending and transverse colon were defined as proximal tumor, while the distal tumor includes the tumors located in descending colon, sigmoid colon, and rectum.(21) This study was approved by the Institutional Review Board of the Six Affiliated Hospital of Sun Yat-sen University and conducted in…”
MethodNGUYEN, S. V., Shamoun, L., Landerholm, K., Andersson, R. E., Wågsäter, D., & Dimberg, J. (2021) · In Vivo · doi:10.21873/invivo.12339 · Cited by 8
Wu, W., Li, D., Ma, W., Zheng, S., Han, D., Xu, F., Yan, H., & Lyu, J. (2021) · Cancer Control · doi:10.1177/10732748211064034 · Cited by 8
“Differences in histological features, clinical manifestations and patient prognoses between LCC and RCC have been widely reported.(4,5) Regarding morphology, RCC tumours are flatter and less likely to be detected using colonoscopy in the early stages; therefore, diagnosed patients often have more advanced disease and…”
BackgroundLi, L., Du, X., & Fan, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.787208 · Cited by 10
Horowitz, M. A., Li, M., Parker, M., Arbuiso, A. G., Gensler, R., Sahebjam, S., Redmond, K. J., Le, D. T., Gabre-Kidan, A. A., Azad, N., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05107-9 · Cited by 8
“Left sided tumors (i.e. those located near the rec-tosigmoid junction and rectum) have previously been found to be associated with BM development [30, 31 ].”
Tashkandi, E. M. (2025) · Cancer Management and Research · doi:10.2147/cmar.s554044 · Cited by 7
“…primaries, while right-sided tumors, typically linked with adverse biology were less common, consistent with Angelakas et al and Baran et al 20,21 RAS and BRAF mutations were detected at lower frequencies than in older-onset CRC, possibly reflecting distinct EOCRC biology or limited testing…”
Amonkar, M. M., Chase, M., Myer, N. M., Wang, T., Turzhitsky, V. M., & Spira, A. I. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100712 · Cited by 11
Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes
Herold, M., Szász, A. M., Szentmártoni, G., Martinek, E., Madar-Dank, V., Barna, A. J., Mohácsi, R., Somogyi, A., Dank, M., & Herold, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-40216-3 · Cited by 10
“The sidedness of the tumor was described as detailed by Baran et al. 46 Due to the large number of combinations in patients’ chemo-therapeutic treatments, the lineage number of the final treatment the patient received was recorded.”
BackgroundKryczka, J. M., & Boncela, J. (2023) · Cancers · doi:10.3390/cancers15235623 · Cited by 7
“One of the most critical reasons is high molecular heterogeneity within CRC, resulting in substantial differences in treatment response to both chemo-and immune-therapy [4].”
BackgroundColorectal Cancer: 35 Cases in Asbestos-Exposed Workers
Porzio, A., Feola, A., Parisi, G., Lauro, A., & Campobasso, C. P. (2023) · Healthcare · doi:10.3390/healthcare11233077 · Cited by 7
“According to Baran et al. [28], the CRC anatomical location was assessed as follows: the right-sided colon cancer, from the cecum to the not-included splenic flexure; the left-sided colon cancer, from the splenic flexure to the rectum; and the rectum cancer.”
High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients
von Koskull, A., Hagström, J., Haglund, C. H., Kaprio, T., & Böckelman, C. (2024) · Biomarkers · doi:10.1080/1354750x.2024.2321916 · Cited by 7
“…with right-sided tumors often more poorly differentiated because they are harder to detect and often further progressed at the time of detection (Baran et al. 2018). colon tumors can also be differentiated using the consensus molecular subtype (cMs) classification, with differences in…”
BackgroundIshizuka, M., Shimizu, T., Shibuya, N., Takagi, K., Hachiya, H., Nishi, Y., Suda, K., Aoki, T., & Kubota, K. (2020) · The Oncologist · doi:10.1002/onco.13555 · Cited by 7
Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience
Sharma, A., Sharma, A., Sharma, V., Kumar, S., Kumar, A., Deo, S. V. S., Pathy, S., Shukla, N., Pramanik, R., Raina, V., et al. (2021) · South Asian Journal of Cancer · doi:10.1055/s-0041-1736343 · Cited by 7
The implication of BRAF mutation in advanced colorectal cancer
O’Riordan, E., Bennett, M., Daly, L. E., & Power, D. G. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02689-x · Cited by 7
“1 3 This may be due to a variety of reasons, including underlying genetic mutations or potential environmental differences including bacterial populations and exposure to bile salts [24].”
BackgroundAn immunocompetent rectal cancer model to study radiation therapy
Kim, J. K., Wu, C., Latto, M. D., Gao, Y., Choi, S., Kierstead, M., Sauvé, C.-E. G., Fırat, C., Perez, A. C., Sillanpaa, J. K., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100353 · Cited by 10
“These models should also provide an opportunity to develop novel effective therapy regimens involving immunomodulators for the treatment of RC, which has been reported relatively less sensitive to the current immunotherapy compared with right-sided colorectal cancer.(8) Numerous murine models of colon cancer have been…”
BackgroundClinicopathological Differences between Right and Left Colorectal Cancer by Sex
Ra, H., Jeong, S., Lee, H., Chung, J., Kim, K. O., Lee, W., Kim, J., Kwon, K. A., & Kim, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102810 · Cited by 7
“This is because the molecular biological mechanisms, symptoms, and signs differ depending on the location of CRC [2,3].”
BackgroundHemmati, M., Wudy, S. I., Hackbarth, F., Mittermeier-Kleßinger, V. K., Coleman, O. I., Haller, D., Ludwig, C., Dawid, C., & Kleigrewe, K. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00771 · Cited by 7
Zhang, C., Zhang, L., Huang, Q.-Y., Jiang, S., Peng, T., Wang, S., & Xu, X. (2024) · Oncology Letters · doi:10.3892/ol.2024.14594 · Cited by 7
“CRC located in the proximal colon (right) and distal colon (left) were previ‑ ously found to exhibit different molecular characteristics and histology, suggesting that the pathogenesis of CRC depends on tumor location (23).”
BackgroundAderibigbe, A. S., Dare, A. J., Kalvin, H. L., Olasehinde, O. O., Wuraola, F. O., Adisa, A., Omisore, A. D., Komolafe, A. O., Omoyiola, O. Z., Okereke, C. E., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27878 · Cited by 7
“Tumors in the proximal colon exhibit different molecular characteristics and histologic profiles, with alternative pathways — namely, microsatellite instability and the CpG island methylation pathway — driving CRC tumorigenesis, presentation, and treatment responsiveness [21].”
Herold, Z., Herold, M., Szentmártoni, G., Szalasy, R., Lohinszky, J., Somogyi, A., Szász, A. M., & Dank, M. (2025) · Medical Sciences · doi:10.3390/medsci13030108 · Cited by 6
“The location of CRC was described as rectal cancer, right-sided, left-sided, and at multiple sites, as described previously [22].”
Prejac, J., Kekez, D., Belev, B., Prejac, M., & Pleština, S. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1900300 · Cited by 6
“Right-sided colon cancer has been recognized as a more aggressive disease, usually associated with RAS, PIK3CA, SMAD4, BRAF, and PTEN mutations, peritoneal carcinomatosis, and shorter overall survival (30, 31).”
BackgroundProfil dan Kesintasan Penderita Kanker Kolorektal RS Bethesda Yogyakarta
Supono, E. A., Jayadi, T., Hariatmoko, & Siagian, J. W. (2023) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v29i3.2547 · Cited by 6
Emile, S. H., Horesh, N., Garoufalia, Z., Gefen, R., Salama, E., & Wexner, S. D. (2024) · Surgery · doi:10.1016/j.surg.2024.02.028 · Cited by 6
Gu, C., Jin, L., Lv, X., Wang, C., Wen, C., & Su, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01421-2 · Cited by 7
Muñoz-Cabello, R. A., Ramos, A. A., Miranda, F. J., Rosa, J. A. F., Muñoz, A. E., Ramírez, A. A., Chavez, E. P., Gallardo, G., & Pizarro, S. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.10.018 · Cited by 6
Esfandiari, F., Bakhshi, B., Shahbazi, T., Derakhshan-Nezhad, E., Bahroudi, M., Minaeian, S., Boustanshenas, M., Alborzi, F., Behboudi, B., & Fazeli, M. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294053 · Cited by 7
Research progress on the diagnostic value of fecal calprotectin in colorectal tumors
Jing, W., Sun, J., Wu, Q., & Zhang, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1626197 · Cited by 6
Пузанов, Г. А., Astier, C., Papakonstantinou, D., Londoño, M. Q., Blériot, C., Yurchenko, A. A., Bani, M. A., Jules-Clément, G., André, F., Marabelle, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218127 · Cited by 6
An investigation on the c‐MYC, AXIN1 , and COL11A1 gene expression in colorectal cancer
Moradifard, S., Minuchehr, Z., & Ganji, S. M. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2229 · Cited by 7
Kubeček, O., Laco, J., Špaček, J., Kubečková, A., Petera, J., Krulichová, I. S., Bezrouk, A., Filip, S., & Kopecký, J. (2021) · Current Oncology · doi:10.3390/curroncol28040255 · Cited by 6
“It is now clear that the right and left colon have different embryonic origins, thus explaining why the tumors originating from them display diverging mutations and metastatic patterns [9].”
BackgroundBi, L., Zhou, Y., Zhang, Y., & Zhang, X. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.1.20 · Cited by 6
“As reported by previous research, CIN and MSI pathways are crucial pathways in LSCC and RSCC [5].”
BackgroundNational screening for colorectal cancer is associated with stage shift to earlier diagnosis
Sarofim, M., Ashrafizadeh, A., Gill, A. J., Silva, K. D., Evans, J. P., Clarke, S. J., Pavlakis, N., Norton, I. D., & Engel, A. F. (2024) · ANZ Journal of Surgery · doi:10.1111/ans.18985 · Cited by 6
Koržinek, M., Ćelap, I., Fabijanec, M., Žanić, T., Ljubičić, N., Baršić, N., Verbanac, D., Barišić, K., & Rajković, M. G. (2024) · Acta Pharmaceutica · doi:10.2478/acph-2024-0036 · Cited by 6
“…are some of the major risk factors for the development MARTHA KORŽINEK 1 IVANA ĆELAP 1,2 MARIJA FABIJANEC 1 TENA ŽANIĆ 1 NEVEN LJUBIČIĆ 3 NEVEN BARŠIĆ 3 DONATELLA VERBANAC 1 KARMELA BARIŠIĆ 1 MARIJA GRDIĆ RAJKOVIĆ 1, * of CRC, with most cases diagnosed in individuals over 50 years old (2, 3).”
Predicting colorectal polyp recurrence using time-to-event analysis of medical records
Harrington, L. X., Wei, J., Suriawinata, A. A., MacKenzie, T. A., & Hassanpour, S. (2019) · PubMed Central · doi:10.48550/arxiv.1911.07368 · Cited by 6
Perirenal Fat Surface Area and Oncologic Outcome in Elective Colon Cancer Surgery
Eckberg, S. E., Dahlberg, M. J. A., der Hagopian, O. S., Farahnak, P., Sandblom, G., Nordenvall, C. A. M., & Everhov, A. H. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001746 · Cited by 6
“0011* Complication ≥Clavien–Dindo 3, n (%) 181 (25) 32 (17) 85 (23) 64 (35) 0.”
Luo, Z., Fu, Z., Li, T., Zhang, Y., Zhang, J., Yang, Y., Yang, Z., Li, Q., Qiu, Z., & Huang, C. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709835 · Cited by 6
Liquid Biopsy im kolorektalen Karzinom
Haupts, A., Roth, W., & Hartmann, N. (2019) · Der Pathologe · doi:10.1007/s00292-019-00698-3 · Cited by 8
Livingston, A. J., & Bailey, C. E. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09522-2 · Cited by 6
Right vs. Left colorectal cancer – Where do we draw the line?
Lansom, J. D., Liew, I., Ng, K., Ly, T., Naidu, K., Chapuis, P. H., & Chan, C. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105634 · Cited by 6
Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer
Edin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren‐Burström, A., Guelpen, B. R. V., Ling, A., Ljuslinder, I., & Palmqvist, R. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546406 · Cited by 5
“27 A pre-dominant right-sided localization has previously been reported for PD-1/PD-L1.”
Pérez‐Santiago, L., Pascual, D. H., Lara, J. S. S., Huerta, M., & Dorcaratto, D. (2026) · Cancers · doi:10.3390/cancers18030489 · Cited by 5
“…of colorectal liver metastases, DFS and overall survival (OS) are comparable between right-sided and rectal primaries, and that these (rectal primaries) exhibit worse outcomes than left-sided cancers, supporting the distinction between these two locations when assessing risk factors [76–78].”
El‐Hussuna, A., Knudsen, M., Frasson, M., & Poulsen, L. Ø. (2023) · BJS Open · doi:10.1093/bjsopen/zrac153 · Cited by 5
Vink‐Börger, E. M., Dabir, P. D., Krekels, J. P. M., van Kouwen, M. C. A., Ligtenberg, M. J. L., van der Post, R. S., & Nagtegaal, I. D. (2024) · Histopathology · doi:10.1111/his.15150 · Cited by 5
“15,16 However, 0.13% is considerably lower than expected, based on both the incidence of LS (3% of all CRC) 17 and the high prevalence of dMMR in LS-associated advanced adenomas (80%).”
BackgroundInfluentialRom, A. D., Dragičević, S., Janković, R., Škodrić, S. R., Sabljak, P., Marković, V., Rosic, J., Barisic, G. I., & Nikolić, A. (2024) · Diagnostics · doi:10.3390/diagnostics14141512 · Cited by 5
“In the mucinous tumor group, there were more tumors of the right colon, while non-mucinous tumors were predominantly located in the left colon and rectum, as confirmed by other studies [8,55,56].”
ResultMuttillo, E. M., Causi, F. S. L., Franca, A. L., Lucarini, A., Arrivi, G., Cicco, L. D., Castagnola, G., Scarinci, A., Mazzuca, F., Balducci, G., et al. (2024) · Cancers · doi:10.3390/cancers16193314 · Cited by 5
Fwelo, P., Adekunle, T. E., Adekunle, T. B., Garza, E. R., Huang, E. S., Lawrence, W. R., & Ewing, A. P. (2025) · Cancer Medicine · doi:10.1002/cam4.70612 · Cited by 5
NOS2 Polymorphism in Aspect of Left and Right-Sided Colorectal Cancer
Klusek, J. E., Lewitowicz, P., Obłap, R., Orlewska, E., Witczak, B., Marzec, M., Kozłowska-Geller, M. A., Nawacki, Ł., Wawszczak-Kasza, M., Kocańda, K., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040937 · Cited by 5
“This is consistent with global reports indicating that tumors found in RCRC often manifest as mucinous adenocarcinomas [15,37–39].”
BackgroundResultInfluentialAwad, H., Elshebli, S., Hasan, K., Eid, Y., Obeidat, F. N., Alzyoud, M., Alakhras, B., & AlShammas, F. (2024) · Diagnostics · doi:10.3390/diagnostics14161743 · Cited by 5
“Right-sided tumors are known to have more mutations in mismatch repair genes than left-sided ones [40].”
BackgroundAiroldi, M., Bartolini, M., Fazio, R., Farinatti, S., Daprà, V., Santoro, A., & Puccini, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01601-x · Cited by 8
Appendiceal adenocarcinoma with breast metastases
Davies, T., Chouari, T. A. M., Ray, C., & Elgammal, S. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-240808 · Cited by 5
Nwanaji‐Enwerem, J. C., Nze, C. C., & Cárdenas, A. (2021) · Epigenetics Communications · doi:10.1186/s43682-021-00004-4 · Cited by 6
“Likewise, the observation that epigenetic aging may differ based on colon location may be related to differential embryonic origins but is not fully understood [14, 23].”
BackgroundLongitudinal Analysis of 1α,25-dihidroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer
Mühl, D., Herold, M., Herold, Z., Hornyák, L., Szász, A. M., & Dank, M. (2022) · Cancers · doi:10.3390/cancers14030658 · Cited by 5
“Right-sided tumors are known for their increased disease severity [58], therefore, the observation above fits into the knowledge so far; additionally, the latter may be also related to lighter disease severity/lower tumor burden, with high probability.”
BackgroundJin, X., Wu, Y., Feng, Y. W., Lin, Z., Zhang, N., Yu, B., Mao, A., Zhang, T., Weiping, Z., & Wang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899659 · Cited by 5
[Clinical and histopathological characteristics of malignant colon tumors by location]
Flores-Altamirano, M., Montiel-Jarquín, A. J., López-Colombo, A., López-Bernal, C. A., García-Galicia, A., & Garza-Sánchez, J. (2023) · PubMed Central · doi:10.5281/zenodo.8316445 · Cited by 6
Body, A. L., Latham, S., Kong, J. B., Raghunath, A., & Segelov, E. (2021) · Digestive Medicine Research · doi:10.21037/dmr-20-159 · Cited by 5
“Right sided tumours are associated with higher rates of MSI (42).”
BackgroundSud, R., & Mujeeb, V. R. (2022) · Asian Pacific Journal of Cancer Care · doi:10.31557/apjcc.2022.7.1.91-100 · Cited by 5
“Left-sided cancer is less immunogenic, whereas righted-sided cancer is highly immunogenic, and hence right-sided tumor respond to immunotherapies [12].”
BackgroundInfluentialGulubova, M. V., Chonov, D. C., Ignatova, M., & Yovchev, Y. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0022 · Cited by 4
Disparities in Advanced Stage Colorectal Cancer Outcomes in Appalachia: A Comprehensive Review
Wang, C. C., Farmer, T., Garland‐Kledzik, M., & Magge, D. R. (2025) · The American Surgeon · doi:10.1177/00031348241312124 · Cited by 4
“29 Access to lower endoscopy, speci fi cally screening colonoscopy, is another multifactorial consideration when stratifying the risk of presenting with advanced stage disease.”
Gohla, G., Archid, R., Hoffmann, R., Kübler, J., Munzel, M., Königsrainer, A., Nadalin, S., Nikolaou, K., & Winkelmann, M. T. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1979257 · Cited by 4
“cancer was noticeably poorer than that of left-sided colon cancer [33,34].”
BackgroundQuintero, M., & Bangi, E. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113370 · Cited by 5
“This type of variability is also commonly observed in human colon tumors, 70,71 so while not surprising, it introduces a degree of variability across experiments that can be challenging.”
Alfonsín, G., Berral-González, A., Rodríguez-Alonso, A., Quiroga, M., Rivas, J. D. L., & Figueroa, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031919 · Cited by 4
“It is well established that depending on the location of the tumours (right or left side of the colon), different molecular characteristics are detected as well as different behaviour in disease progression, overall survival and response to therapy [30].”
BackgroundValladares, C. T., Valenzuela, G., González, E., Maureira, I., Toro, J., Freire, M., Sepúlveda-Hermosilla, G., Ampuero, D., Blanco, A., Gallegos, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094695 · Cited by 5
Heriyanto, D. S., Yoshuantari, N., Akbariani, G., Lau, V., Hanini, H., Hidayati, Z., Arief, M. Z., Gunawan, A. N., Ridwanuloh, A. M., Kusharyoto, W., et al. (2024) · World Journal of Oncology · doi:10.14740/wjon1843 · Cited by 5
“Right-sided CRC often has flat histopathology and a DNA MMR pathway deficiency [76].”
BackgroundCuello, H., Sinha, S., Verhagen, A., Varki, N. M., Varki, A. P., & Ghosh, P. (2024) · JCI Insight · doi:10.1172/jci.insight.181539 · Cited by 6
“…risk for progression to CRCs. Consistent with the fact that cancers that originate from right-sided polyps are often diagnosed at advanced stages (36), a CRC array and multivariate analyses showed that Siglec-XII positivity was significantly associated with presentation at advanced stages (pTNM;…”
BackgroundRadić, J., Nikolić, I., Kolarov-Bjelobrk, I., Vasiljević, T., Djurić, A., Vidović, V., & Kožik, B. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080879 · Cited by 5
“Based on literature data [35], RCC is predominantly diagnosed at advanced stages of the disease, although we did not observe a statistically significant difference in the distribution of disease stages based on the tumor location ( p = 0.283).”
BackgroundInfluentialJustesen, T. F., Orhan, A., Rosen, A. W., Gögenur, M., & Gögenür, I. (2024) · Annals of Surgery Open · doi:10.1097/as9.0000000000000499 · Cited by 4
Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations
Parikh, P. M., Bahl, A., Sharma, G., Pramanik, R., Wadhwa, J., Bajpai, P., Jandyal, S., Dubey, A. P., Sarin, A., Dadhich, S. C., et al. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0044-1791689 · Cited by 4
Ramadan, M. M., Alfayea, T. M., Alsofyani, A. A., Alzahrani, M., Alyabsi, M., AlHusseini, D. N., & Algarni, A. S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100632 · Cited by 4
Su, A., Pedraza, R., & Kennecke, H. F. (2023) · Current Oncology · doi:10.3390/curroncol30040279 · Cited by 5
“dMMR is present in 15–17% of colorectal cancers and is found predominantly in right-sided malignancies [13,14].”
BackgroundSahu, N. P., Agrahari, A. K., Parida, B., & Das, S. (2023) · AL-Kindy College Medical Journal · doi:10.47723/kcmj.v19i3.1218 · Cited by 4
Çoruh, A. G., Uzun, Ç., Bozca, E., Bozca, B., Demir, İ. B., Atasever, H. G., Göçtürk, B., Bakırarar, B., & Akyol, C. (2020) · Polish Journal of Radiology · doi:10.5114/pjr.2020.99848 · Cited by 4
Analysis of Mono-ADP-Ribosylation Levels in Human Colorectal Cancer
Wang, C., Tang, Y., Li, M., Xiao, M., Li, Q., Yang, L., Li, X., Yin, L., & Wang, Y. (2021) · Cancer Management and Research · doi:10.2147/cmar.s303064 · Cited by 4
Sarandria, N. (2022) · Journal of Cancer Therapy · doi:10.4236/jct.2022.1312059 · Cited by 4
A Retrospective Study of the Prognostic Patterns in Colorectal Cancer Patients
Patil, J. D., Mohamed, Y. M., & Almarzooq, R. (2023) · Cureus · doi:10.7759/cureus.38522 · Cited by 4
“RCRC tends to have poorer histological grading, staging, and even prognosis compared to primary tumors arising from the left side.”
BackgroundResultInfluentialSarmiento-Machado, L. M., Rodrigues, M. A. M., Romualdo, G. R., & Barbisan, L. F. (2024) · PubMed · doi:10.14670/hh-18-692 · Cited by 4
Role of miRNAs in Sigmoid Colon Cancer: A Search for Potential Biomarkers
Marques, D., Ferreira-Costa, L. R., Ferreira-Costa, L. L., Bezerra-Oliveira, A. B., Corrêa, R. D. S., Ramos, C. C. D. O., Vinasco‐Sandoval, T., Lopes, K. D. P., Vialle, R. A., Vidal, A. F., et al. (2020) · Cancers · doi:10.3390/cancers12113311 · Cited by 4
“CRC is not a single type of tumor and its pathogenesis depends on the anatomic location [4], differing between the colon (which is subdivided into seven parts: cecum, ascending, hepatic flexure, transverse, splenic flexure, descending, and sigmoid) and rectum [5].”
BackgroundHematological markers as prognostic predictors in patients undergoing colon cancer surgery
Stuva, J. P. G., Pérez-López, C., Romero, M. S. R., García, A. B., Vivas, P., Ripoll, D., & Gordo, S. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-33554-x · Cited by 3
“The RC includes the cecum to the transverse colon, and the LC includes the splenic flexure to the rectosigmoid junction 10 .”
InfluentialZhang, Z., Xu, J., Wu, Y., Liu, T., Zhang, J., Zhou, M., Qiao, J., Pan, H., & Wang, X. (2026) · Cell Proliferation · doi:10.1111/cpr.70260 · Cited by 3
“Consistent with prior research, our results also suggested a more immunologically active microenvironment in right-sided CRC [6].”
InfluentialNgalim, S. H., Yusoff, N., Johnson, R. R., Razak, S. R. A., Chen, X., Hobbs, J. K., & Lee, Y. Y. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.09.003 · Cited by 3
Zhu, S., Tu, J., Pei, W., Zheng, Z., Bi, J., & Feng, Q. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02991-1 · Cited by 3
Colorectal cancer in the young – outcomes following surgical management?
Newton, L., Munro, T. N., Hamid, M., & Shabbir, J. (2021) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2021.0049 · Cited by 3
Metadata
- Authors
- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y.
- Affiliations
- Dokuz Eylül University (TR)
- ORCID
- Acar, Emine
- Venue
- Gastroenterology Research
- Publisher
- Elmer Press, Inc.
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 264-273
- ISSN
- 1918-2805 (ISSN-L)
- 1918-2813
- PMC
- PMC6089587
- OpenAlex
- W2887365295
- Cited by
- 553
- References
- 113
- Citations by year
- 2026: 62 · 2025: 59 · 2024: 117 · 2023: 76 · 2022: 66 · 2021: 90 · 2020: 56 · 2019: 25 · 2018: 2
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Gastroenterology Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- left-sided colorectal cancer, right-sided colorectal cancer, tumor location, mismatch repair deficiency, chromosomal instability, KRAS mutation, APC mutation, PIK3CA mutation, TP53 mutation, adjuvant chemotherapy, 5-fluorouracil, anti-EGFR therapy, immunotherapy, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.